General Announcement::GPL receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-Oct-2019 11:29:52
Status
New
Announcement Sub Title
GPL receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules
Announcement Reference
SG191009OTHRN29C
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/10/2019 09:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

Attachments

PR_SGX_09102019.pdf
Total size =3246K